New hope for Tick-Bite survivors: mast cell drugs aim to ease lingering symptoms
NCT ID NCT07526558
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether medications that calm mast cells (ketotifen and cromolyn) can safely reduce persistent symptoms like fatigue, pain, and brain fog in people who had a tick-borne illness. Fifty adults aged 21-65 will receive either one of these drugs or a standard antihistamine (fexofenadine) for 12 weeks. The goal is to see if the mast cell stabilizers are safe and help more than the usual treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ketotifen, cromolyn sodium, and fexofenadine
- What this could lead to
- If successful, this could point toward a treatment that eases lingering symptoms like fatigue and brain fog after a tick-borne illness.
- What could go wrong
- This is a small, early-phase pilot study with only 50 participants, so results may not apply broadly. The drugs may cause side effects or not improve symptoms more than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-GAL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.